A subgroup of women with ER+/PR+ breast cancers develop recurrence, and molecular assays such as the Recurrence Score and Breast Cancer Index are helping to identify ER+/PR+ breast cancer patients requiring hormonal and/or chemotherapy [53]. This evidence concerns the gene PGR and breast carcinoma.